He definitely gets around.

Think he has a website where he has all his plays, shorts and longs, at least that what i remember when I traded more.

Got luck with Geron,

Well, if you say so.

My recollection of Clay was a great guy who had an incredible talent for reading the charts, and was very generous with sharing that information.

Cheers,

In it's current form, it is most definitely a rigged game for the uber wealthy.

Say goodbye to democracy

Whoa ClayTrader has shown up...

From memory of trading years past, he was incredibly accurate...

Ask Jesus, just kidding...

This is just the ones who know that are accumulating and the ones looking to flip a quick buck are getting frustrated and selling into their hands...

Same old, same old...

If you are looking to trade, you may have caught a good time with ASH coming up...

...but most who trade this stock end up losing...

If you are long term investor, buy and forget about it...

Cheers,

geron is on its own course and is heavily manipulated

the pps is not real nor are the bs ups & downs, it is because some are accumulating as some are selling.

in my opinion, larger hands are accumulating here and retail is selling to them...

such is the way of the world today...

I agree Crawford.

The hedgies and pharma manipulate this like there would be no laws. And in a sense, they are right, because for some the laws simply don't count when we have no one really doing enforcement anymore.

From my experience, just when they create the worst sentiment is when we are about to go up...

I hope any who are involved in manipulating this stock, that could help sick people, for unethical monetary gains, are one day going to meet their karma.

Cheers,

from yahoo...

We can expect 2 abstracts at ASH and, separately, MDS-RARS and blast phase MF data publication(s) or at a separate meeting
We have been informed by Dr. Tefferi that he has submitted data from the Myelofibrosis IST as an abstract to be considered for presentation at the American Society of Hematology or ASH annual meeting to be held in San Francisco in December. The abstract contains safety and efficacy data from patients with MF which have been updated since his presentation at ASH 2013.

Unfortunately, updated data sets from the MDS-RARS and blast phase MF patients were not available to Dr. Tefferi at the time of the ASH abstract deadline and as a consequence he did not submit abstracts to ASH regarding the treatment outcomes in these IST cohorts.

These data sets were not available because of the extensive data entry and analysis required to update the MF IST cohort data sets in order to support the preparation of this complete response to the FDA partial hold as well as the activities required to prepare for the transfer of the IND and study sponsorship for Mayo Clinic to Geron.

We look forward to the data from the patients with MDS-RARS and patients with blast phase MF being presented or published by Dr. Tefferi at a future venue.

This year we have also initiated collaborations with a select group of academic investigators who are looking into the effects of the imetelstat in non-clinical models of MF and other myeloid malignancies such as AML.

From these studies we may gain insight into the potential mechanisms of action of our drug in these malignances as well as non-clinical data to support broader clinical development of imetelstat. We’re pleased to report that our collaborators have submitted some of these data as abstract for ASH 2014. In keeping with standard ASH embargo policy, I will not be making any further comments on any of the submitted data from the collaborators.

By December we should have a much better idea of what is going on, IMO...

Possibly in late November early December...

http://www.hematology.org/Annual-Meeting/General/2904.aspx

-------------------------------------------------------------------------------------------

ASH is coming; Abstracts in early Nov.; Conference in early Dec.
ASH will be the milestone for Imetelstat. With a number of new papers coming (at ASH & in other publications) concerning Imetelstat (for MF, in combination with other drugs, in trials {animals & humans} for other types of cancers, new genetic markers) the future of Imetelstat appears assured. There has already been a telomere-telomerase Nobel Prize, with other awards likely. The corporate future of Geron, with partners or a new owner, is in the oven, but the primary ingredient (Imetelstat) is safe and beneficial. Mayo Clinic has been the most important factor in developing Imetelstat for human trials, and maintains a very strong involvement in current and future applications. The FDA is on Mayo's side (hold released).

----------------------------------------------------------------------------------------

The publicity from ASH, no negative news about Imetelstat, and Mayo Clinic's successes will drive the PPS much higher. Geron will not try to go it alone. I don't know if they will choose a partner or a merger, but Imetelstat has no opposition in science and medicine that I can find. Market factors are still with us, but ASH will take care of them. This drug is too good. Amgen's work with combinations is amazing.

-----------------------------------------------------------------------------------

ASH will determine the future of Imetelstat and Geron. Either Imetelstat is a great drug (with future potential), or we have been misled. There is no way to hide the truth after the ASH presentations. I have not seen any negative papers to date (anywhere), so I am hoping for the best.

---------------------------------------------------------------------------------------

Everyone on this board is expecting good news at ASH concerning Imetelstat. Are there any "nay-sayers"? ASH seems to be the point-of-no-return, and the place that will turn the stock up, and, perhaps, reveal a partner.

-----------------------------------------------------------------------------------------

I waiting for ASH, and Imetelstat papers.

The problems that are keeping Geron's PPS at such a low level are two fold: FDA hold, Geron as an organization. As others have said Geron owns Imetelstat, but Mayo has conducted the MF trials that has brought Imetelstat to the public's attention, with successes. It appears that everything presented at ASH will be Imetelstat positive. Imetelstat's positives, at some point in time, should translate into a higher Geron PPS. There do not appear to be any Imetelstat negatives. Is Imetelstat part of a universal cancer cure? Is the telomere-telomerase combination active in all cancers and cancer stemcells ? These are questions that will be answered at ASH.

IMO the PPS we see is not real and is highly manipulated...

Interesting posts from yahoo board...

John's Phase I IST Mayo Cohort
The IST conducted by Dr. Tefferi since 2012 under IND NCT 01731952 - the IST that saved his life - is now transferred to Geron as of September 30th. This does not mean John will be flying to Menlo Park. It does mean Geron will collect and report his cohort's data (the Phase I Arm A and B data) starting 9/30/14 with Dr. Tefferi remaining as the principle investigator for Geron instead of Mayo. Lucky Geron!

Dr. Tefferi still works for Mayo (not Geron) so Mayo is not "walking away" from anything . Mayo transferred ownership of the MF study IND NCT 017319 sponsorship to Dr. Tefferi so he could then transfer it to Geron so Geron could sponsor the last 4 months of the Phase I IST MF study still on-going (John's study) and also sponsor Phase II that will include John and many others (closer to home - yeah!) now without any delay (as would be the case if Geron had to wait to proceed under the "old" ET IND on hold). However, the Geron ET IND is now a moot issue and completely irrelevant now! Whether that hold eve comes off or doesn't - makes no difference.

Geron has a "new" IND NCT 01731951 not on hold and can begin Phase II after informing FDA of it's intentions regarding any new studies. That is, that there intention to study MF/ AML/MDA and not ET.

Most importantly, the MF IST at Mayo "ceased enrolling patients in January 2014". "...patients remaining in the study - which includes patients with MF (myelofibrosis), blast phase MF, and refractory anemia with ringed siderobalsts, as sub-type of the rare myelodysplastic syndromes (RARS-MDS) - will continue to receive treatment". This means that - given even latest possible enrollment in January 2014 - some patients have very likely exceeded their prognosis. John's IST Phase I MF patients and other patients are still alive and still in treatment at least 9 months later and most much longer. Don't you now believe the ASH data will be awesome?

-----------------------------------------------------------------------------

ASH will determine the future of Imetelstat and Geron. Either Imetelstat is a great drug (with future potential), or we have been misled. There is no way to hide the truth after the ASH presentations. I have not seen any negative papers to date (anywhere), so I am hoping for the best.

-----------------------------------------------------------------------------------

Advanced Partnership Discussions Under Way
The reason Geron wanted full control of the Mayo IST data is they are in advanced stages of partnership discussion for Imetelstat. The Mayo IST, while only a single center study, is a large enough proof-of-concept to satisfy any partner, especially considering it was conducted by the number one expert in the world, Dr. Tefferi.

Remember, the first Jakafi Phase I/II trial (154 MF/ET/PV patients) was conducted principally by Dr. Tefferi at Mayo Rochester with help from Dr. Verstovsek at MD Anderson (NCT00509899). A smaller Phase II in 41 MF patients was later conducted by Dr. Mesa at Mayo Arizona and Dr. Verstovesek at MD Anderson (NCT01340651). It was Tefferi’s data that Incyte used to convince Novartis to partner with them on Jakafi back in 2009. And it will be Tefferi’s data that Geron uses to partner Imetelstat.

------------------------------------------------------------------------------------

I believe you are correct. ASH will bring forward all the information about Imetelstat that has been processed, and is in publishable form. The year between ASH 2013 and ASH 2014 has not diminished the science and medical successes for Imetelstat, and the amount of information available has dymacically increased. Most of all, the "negatives" that could defeat Imetelstat in the future do not seem to exist. Dr. T's new position as the coordinator of all Mayo-Geron data and trails is significant, and will lead to new paths and partners for Imetelstat, probably before ASH. As others say, "of course, IMO".

-----------------------------------------------------------------------------------

"There is little chance Geron has the wherewithal to advance Imetelstat on its own. The Mayo data proves the drug works and the side effects are manageable. This is exactly what big pharma wants and Geron has noted in most of its road shows its interest in partnering Imetelstat"

This is most of us believe. Scarlett is there to the best deal possible for Imetelstat, and that will be after the revelations of ASH.

------------------------------------------------------------------------------------

Tefferi's trial proved the palliative value of Jakafi with reduction of symptoms and spleen size. That's proof of concept. When a drug works and side effects can be managed, big pharma takes notice. Tefferi chose not to participate any further in Jakafi trials because the drug proved unable to modify the disease. If Jakafi were able to eradicate or suppress the disease, Tefferi would have been thrilled to participate further as the drug's side effects are manageable just like Imetelstat's are.

There is little chance Geron has the wherewithal to advance Imetelstat on its own. The Mayo data proves the drug works and the side effects are manageable. This is exactly what big pharma wants and Geron has noted in most of its road shows its interest in partnering Imetelstat.

lol

Wait until the FDA Hold is removed if you want to see price movement.

In my opinion, the GERN PPS will be much different by the end of the year...

I agree, added this morning another 306 shares...

May not seem like much, but these dips are allowing me to scoop up small amounts each time, adding them to the total, which is quite large and growing...

Don't like that the PPS is at these levels, but while they are the feasting on new shares is good.

a view from yahoo board...

We have known since March that the timeline for the PH2 trial was pushed back 6 months from July to first Q of 2015. That didn't change. Chip could have pushed it back, but did not. That really is not the end of the world.

There was always the primary request of the FDA to track LFTs to baseline, and Scarlet said "what takes a long time to happen takes a long time to unhappen". Geron needs to track down patients, get their IRB approval, get patient approval to take new blood samples, and then track the results- possibly for months.
This hasn't changed. There has not been bad news regarding LFTs- quite the opposite, MC was released and it is fair to assume the LFTs were not an issue. This will continue.

Geron is getting the Mayo IND at the end of September, however and even more important, they already have (or are almost complete) all the DATA from Mayo, and that is VERY significant. They are using that data "to inform the the new Phase 2 trial" which means they are certainly moving forward and the data from MC will help inform them on dosages, mylosuppressive effects etc. This is very good news.

The 33 patients still enrolled in the Mayo all have CI or PR or CR. That seems remarkable and also not fully appreciated. We don't know exactly the status of the MDS patients, but we do know that every single one is still enrolled more than 8 months later. I find this significant and almost astonishing.

Other than a few investors that inexplicably hoped for a hold release, nothing new or bad occurred on the call, quite the opposite. Time line still in tact. Data being transferred. Tefferi on-board. Patients in remission- MANY patients. Maybe a filing with the FDA after the transfer at end of Sept? Followed by release in Oct? Followed by by abstracts in November? Followed by ASH in December? Followed by upgrades in DEC?JAN? Followed by MDS studies in FEB? ETC ETC...

Take a breath. Let unknowledgeable traders abandon ship and long term investors make multiples of $$$

"it's nothing but dead money till then. Tiresome..."

It must not seem good to those who are here to trade GERN stock...

GERN is a hard stock to trade, as discovered by many who have tried...

I respectfully disagree. I don't think it is anything we can point to.

Otherwise why would the big dollars, institutions now hold more of GERN than they ever have.

We can figure out more than they can..?
With their stock pros and medical staff analyzing all data..?

In my opinion the PPS is effected by manipulation and the Tea Party Right, who still associate GERN with Stem Cells, and have worked endlessly to put the company out of business.

If you then add in that GERN is the largest threat to many drug companies who make billions on other treatments...that will hit their bottom line hard once GERN gets traction...

...you end up with a situation that is very hard for the common man like us to see where or what is influencing the SP...

That is why, in my opinion, this is such a hard stock to trade...

from another poster...

"The simple reason that Dr. Tefferi transferred ownership/sponsorship of MF IND 1951 to Geron is so patients would not have to wait 5 more months for FDA to lift the hold on Geron's ET IND and could begin the planning and implementation of the MF Phase II trials now under MF IND 1951, The simple reason that Dr. Tefferi also transferred the ongoing MF IST (MF Phase I) is because that trial was conducted under MF IIND 1951 that now belongs to Geron so they must also sponsor the MF IST that was planned to end in March 2014 anyway. The simple reason that IND 1951 transferred from Mayo to Dr. Tefferi to Geron is because, to the best of my understanding, FDA allows investigator to sponsor transfers not sponsor to sponsor transfers. The simple reason that the transfer occurred is because it is standard and common practice in the medical research community.

I do not think the transfer occurred because for 16 months I constantly said to Dr. Tefferi in a very whiny and annoying voice, "When can John be treated at home?" This was the equivalent of the backseat: 'are we there yet?' 'how much longer', 'why is it taking so long?' 'can you drive faster'?

Disclaimer: 100% of this post is my conjecture. However, it is based on considerable research effort piecing together public information. The same research effort that found Dr. Tefferi and his MF Imetelstat IST proof of concept trial and got John the last seat in it (Arm B). However, it is still my own amateur research and subject to error."

The SP is a hard call on GERN, always has been, that is why it is not a good stock to trade...it does not follow much logic.

For a long investor like myself, this latest move indicates to me that they can now proceed unhindered by the Hold the FDA put on them, as it no longer applies.

So they get an IND and apply for P2 trials...then they will be looked on for partnership.

Once results start coming from P2, maybe even before with the aging demographics we have, and then, if the longs are right, the price per share would be in a different class than today.

It is a hard call to trade or not, especially as I have been in a loss position for most of my time in GERN.
But these downs I can live with and they won't change my life.

What I could not live with is to be given a chance to invest in a world changing technology, and traded out my position for some meager gains.
Then watch the technology take over the world and others get rich.
THAT I could not live with comfortably...

So each to their own...in my opinion...

Why would Tefferi want to be so involved if there was not promise here..?
That's what I see...

another poster...
"Tefferi now wears two hats, as an employee of Mayo, and as the medical and scientific director at Geron responsible for MF studies (in progress and coming). The FDA has shown little confidence in Geron, while lifting the Mayo hold. Our investment is in "Tefferi Oncology Corp." for all practical purposes. Tefferi's skills will determine the future of Imetelstat, and the value of Geron. Mayo and the FDA do not want the research and viability of this medicine lessened by inexperienced hands. It is too important as part of a breakthrough technology."

Her husband seems to be okay with the recent changes...from yahoo board...

John's Phase I IST Mayo Cohort
The IST conducted by Dr. Tefferi since 2012 under IND NCT 01731952 - the IST that saved his life - is now transferred to Geron as of September 30th. This does not mean John will be flying to Menlo Park. It does mean Geron will collect and report his cohort's data (the Phase I Arm A and B data) starting 9/30/14 with Dr. Tefferi remaining as the principle investigator for Geron instead of Mayo. Lucky Geron!

Dr. Tefferi still works for Mayo (not Geron) so Mayo is not "walking away" from anything . Mayo transferred ownership of the MF study IND NCT 017319 sponsorship to Dr. Tefferi so he could then transfer it to Geron so Geron could sponsor the last 4 months of the Phase I IST MF study still on-going (John's study) and also sponsor Phase II that will include John and many others (closer to home - yeah!) now without any delay (as would be the case if Geron had to wait to proceed under the "old" ET IND on hold). However, the Geron ET IND is now a moot issue and completely irrelevant now! Whether that hold eve comes off or doesn't - makes no difference.

Geron has a "new" IND NCT 01731951 not on hold and can begin Phase II after informing FDA of it's intentions regarding any new studies. That is, that there intention to study MF/ AML/MDA and not ET.

Most importantly, the MF IST at Mayo "ceased enrolling patients in January 2014". "...patients remaining in the study - which includes patients with MF (myelofibrosis), blast phase MF, and refractory anemia with ringed siderobalsts, as sub-type of the rare myelodysplastic syndromes (RARS-MDS) - will continue to receive treatment". This means that - given even latest possible enrollment in January 2014 - some patients have very likely exceeded their prognosis. John's IST Phase I MF patients and other patients are still alive and still in treatment at least 9 months later and most much longer. Don't you now believe the ASH data will be awesome?

Hi Trade,

yeah, it was good of subs to post the PR.

The yahoo board is a cesspool, no doubt. But there are a few who are very well versed in bio's, a couple of meds, and one person whose husband is currently enrolled in the current program.

They have had the most informative and spot on comments I have ever read on Geron and have been invested for a long time.

If you read the comments posted I think you will quickly ascertain they are from informed posters only.

This is good news.

Don't watch what the retail market does with a stock that has been a roller coaster for many years, watch what the institutions are doing...
The retail market should be observed by Traders.
The institutions should be observed by Longs.

institutional ownership has increased substantially well before this news today...

in my opinion.

from yahoo board...

Everyone is looking for "hold lifted" and not "IND transferred". Makes the "hold lifted' discussion now null and void. I deem from this point forward no Geron long ever mention the word "hold" again. Geron owns a nice new hold-free IND to use for Phase II. If you research "IND Transfer" (Emory University clinical trial site has nice summary), you will say "why didn't I think of that (me either!). God bless Mayo and Dr. Tefferi.

------------------------------------------------------------------------

it is no longer Mayo's IND. It is Geron's ID. Per the public announcement, Mayo/Dr. Tefferi transferred ownership of IND 01731951 to Geron. Geron now owns that MF IND with no hold on it so Geron can move forward with it's brand new, no holds barred IND. Renders the other ET IND moot and irrelevant. Just google transfers of FDA IND and you will find information about this FDA process. Emory University has a nice summary of it.

--------------------------------------------------------------------------

The Compromise That All Could Accept for Imetelstat
Tefferi is still at Mayo, but is also is the leader of the MF studies at Geron (new and continuing). Mayo's lifted hold allows both Geron and Mayo to move forward with MF, and other "off-label" and new possibilities. Scarlett can seriously bring aboard a deep-pocked partner, with the proper blood cancer credentials. The FDA can put the Geron hold on the back burner as unimportant, since it has nothing to do with MF. Combination drugs can be contemplated. The FDA saves faced for imposing an ill-conceived liver hold. Geron gets to manage all projects using Imetelstat, and Mayo keeps a hand in all of the research. Cancer patients benefit the most. Geron investors get support from the whole "team", and will benefit. Market manipulators have to reevaluated their short positions.

-----------------------------------------------------------------------------

yes no new patients in ongoing MF Phase I IST because that trial has not been recruiting patients since January 2014. However, Geron can begin new studies (Phase II) as soon as they 'communicate' with FDA about new IND and development plans for Imetelstat (read: not planning on developing in ET). This is my interpretation of announcement.

---------------------------------------------------------------------

What will happen? I don't know what you mean - "what will happen soon after those 4 months"? I stated that the MF IST Phase I ongoing Mayo Clinic will continue treating the current cohort through end of year and - by deductive reasoning - until Phase II is implemented. There is no reason for Phase II not to be advanced and implemented now. The NCT 01731951 (publicly available) states that the data for the MF IST Phase I cohort will be published in January 2015 so I think all expect MF IST Phase I cohort currently under treatment at Mayo will not longer be treated in Rochester after that date. However, I doubt patients in remission on Imetelstat will be sent home with no further treatment, do you? I doubt Dr. Tefferi is going to drop all of his patients under treatment, do you?

-----------------------------------------------------------------

Whether or not the "old" ET IND (look up the NCT number for me) is ever lifted (or discussed again) does not matter now. Null...void...moot...irrelevant. Let it go gently into that good night. The brand new MF IND NCT 01731951 is not on hold and we begin again with "no holds barred" with respect to moving on up to Phase II. Do not let your imagination fail you now.

-------------------------------------------------------------------

1. Dr. Tefferi will still work at Mayo Clinic not Geron.
2. Geron will sponsor the last 4 months of the ongoing MF IST Phase I Mayo trial.
3. Dr. Tefferi will still be the principle investigator for the ongoing MF IST Phase I Mayo trial.
4. Geron will advance and implement the MF Phase II trial under it's new IND that Mayo/Tefferi gave them.
5. MF Phase II multi center locations will be announced.
6. MF Phase II multi center IRBs will begin review.
7. MF Phase II patients will enroll.
8. Dr. Tefferi will be the chief study officer (chief PI) of all the PIs at the MF Phase II centers.

Not necessarily in this order.

FYI - Sponsorship does not mean spending or only providing the drug. FDA IND sponsors and investigators have specific roles and responsibilities regarding data collection and reporting only. These duties and obligations are published on the FDA website.

Based on what we are seeing on this board, I would say the current short term TRADERS of GERN stock will end up repeating history.

Gern is not a good stock for trading and has taken the money of many traders.

GERN is a belief story, You either believe in what they are doing, and if so most will be generously awarded...

...or you don't believe in it...
In which case you can Short
OR Trade the stock...

...history seems to indicate that the Shorters make money here, and the Traders usually lose...

Believers, otherwise called LONGS here, buy the dips and wait patiently.

Knock yourselves out...

All bios are down due to fed comments on markets being made by fed on valuations.

GERN because of Hold, is definitely not over valued. But in the absence of news, it follows the market somewhat...

Good time to add.

It is also an International publication, from Israel I believe, so it gives us international exposure where we did not have much before...

It also opens the new Phase 2 trials...

I think one of them is slated for israel...

International reach...

Is anyone else waking up to what is happening here..?

You are a part of History, and most do not even know it...

lol, too funny...
...and some are shorting..? hilarious, imo...

Might also have to do with the fact that our drug can yield Complete Remission in some, whereas this was deemed completely impossible before...

...never before even dreamed of...so when the hold is lifted, it means some could be CURED.

Start seeing what you have here.

CURE for CANCER.

You either believe or you don't or you'll make some dollars trading it...

INCY is the closet competition we have and they can not do what we do.
Thier Market Cap is 9 billion...

Cheers to all,

You're welcome

It is headed in that direction...

What would make you think you would get a good answer to that question...

anyone notice, lol

The bugger got a deal of a lifetime, IMO

I increased my holdings on this dip too, but like usual I never catch the bottom...lol

Have some nice new fresh shares at average 2.17 I think or somewhere close to that...anyway glad to have them,

You either believe or you don't...

New Institutional Ownership Data
From a SA post:

"This is interesting. Institutional ownership numbers for the first quarter are starting to trickle in. Two of the three largest GERN institutional owners, Blackrock and Barclays, added more than 1,000,000 shares each during the quarter ending 3/31/14. I guess they believe the story is still intact, even with the news of the hold that came out on 3/12/14."

Institutional owners would have had two weeks to dump after the news of the hold came out but before the first quarter ended. This can be tracked on the NASDAQ site.

Well, you are definitely one of a kind, at least the first that I have met on MB's...

...you seem like a good man Mark, pleasure to make your acquaintance.

Although I am harsh at times, I too try and hold myself to a higher set of standards, and just don't tolerate easily those who are deceptive and lie as if that was okay...

Certainly had you wrongly pegged though. Thanks for not taking it personally.

Hopefully will be seeing you around the hub,

Cheers Dude,

Trade I think April and beyond will get more and more interesting.

This isn't the normal circumstance, this is the changing of a science...

Some will lose, some will win, but both will fight for their advantage. And I think we are seeing that a little play out now.

But if it is the case, that GERN should become the preferred treatment, then that could be quite valuable...

...as a start, where it can go after that, no body knows...

spidey senses tingling...

from h4chi_1 at yahoo board...

INCY BOD have sold 115$ million in their shares recently. It appears something is happening and its happening fast

---------------------------------------------------------------

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs primarily for oncology and inflammation. The company markets JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF),

Doctors Square Off in Important Battle Over Unapproved Blood Cancer Drug


ASHEVILLE, N.C., March 28, 2014 /PRNewswire/ -- It's hard to imagine heavyweight hematologists publicly squaring off in support of an off-label blood cancer drug. And yet, today, that's exactly what happened in an "Open Letter to the MPN Community of the United States," (http://mpnforum.com/an-open-letter/) published in the April issue of MPNforum Magazine. (www.mpnforum.com)

Photo - http://photos.prnewswire.com/prnh/20140328/PH92830-a

Photo - http://photos.prnewswire.com/prnh/20140328/PH92830-b

The battle is over interferon. With few good alternative therapies for an estimated 300,000 patients in the United States suffering from myeloproliferative neoplasm (MPN), the outcome of the struggle is a life and death issue.

Dr. Hans Carl Hasselbalch, professor of hematology at the University of Copenhagen, Roskilde Hospital, and Dr. Richard Silver, professor of medicine and director of the Leukemia and Myleoproliferative Center at New York Presbyterian-Weill Cornell Medical Center, publicly deplored the efforts of hematologist Dr. Ayalew Tefferi, Professor of Medicine at the Mayo Clinic (Rochester) to minimize the significance of interferon in the treatment of MPNs, a rare chronic leukemia.

"… I am worried," said Hasselbalch, "by the reported claims by Dr. Ayalew Tefferi that interferon is no better than (hydroxyurea) and busulphan in the MPNs. If Tefferi has said so, it is problematic that a colleague, who may be aware of his great impact on the 'scientific community' and MPN-patients' care, stands up and not tells the truth…I cannot dissect or understand the reasons for his anti-IFN attitude."

"I agree with everything [Hasselbalch] says," wrote Silver. "Recombinant interferon is the only drug used in the myeloproliferative diseases that has a physiological basis for its use… instead of the non-specific killing activity of hydroxyurea and other similar compounds."

The Open Letter was triggered by Tefferi's remarks on interferon in a teleconference with an MPN patient group February 23 (http://mpnforum.com/tefferi-speaks/) during which he reported on his upcoming clinical trial of a new MPN drug, Geron's Imetelstat. (Imetelstat was put on clinical hold by the FDA last week, reportedly due to problems in liver toxicity.) Tefferi, a principal investigator in many MPN drug trials, has publicly stated his lack of support for interferon as well as his opposition to an FDA approved myelofibrosis drug, Jakafi.

Citing long clinical experience and publication of many peer-reviewed scientific studies, Hasselbalch and Silver make the case for early use of interferon in MPN treatment.

Recognized as a frontline drug for MPNs in Europe, interferon is only available to US MPN patients as an off-label drug. Interferon is FDA-approved for treatment of other diseases, primarily Hepatitis-C.

MPNforum and its companion MPN Quarterly Journal are open source publications entirely managed and staffed by patients and caregivers with the volunteer participation of scientists and healthcare providers. MPNforum is the largest international on-line monthly magazine devoted to myeloproliferative neoplasm patients and caregivers.

Contact: Zhenya Senyak, Editor, MPNforum
Email

Read more news from MPNforum.

SOURCE MPNforum

http://www.bizjournals.com/prnewswire/press_releases/2014/03/28/PH92830

My personal belief, and it is my opinion only...

is that the american markets are as crooked as a 3 dollar bill.

There is practically no regulation enforcement, naked shorting is still rampant today as ever.

And not one banker has gone to jail yet for the largest BS ever committed...

I think these markets stink to high heaven, and there are those that can manipulate the pps to a point of being able to instill fear, panic or greed, when they are successful in their efforts...then the volume consumes on itself...

...and then they buy or sell to their advantage and for their own ambitions...

I have said for some time that there are those who are accumulating here. I think it is big pharma, in my opinion.

And they want all the shares they can get, regardless of any advantageous finagling they can do, legal or otherwise...

So I think there are those who are accumulating and will do whatever they can to shake your shares...

If the science and execution are good here, it won't matter at what cost you paid, relative to today's price, BUT how many shares you were able to get and hold will be what counts.

If you want to hold Geron long, you have to believe, or you shouldn't try to hold here, in my opinion.

LOL, yes, same here trade, same here...

One of my quotes, "sanity is not a right but a privilege" lol

Cheers

This is not an easy stock for most to hold.

If you want to be a Long with Geron, you have to decide and stick with your decision no matter what.

You are either a believer or not. Is the only way to be a Geron Long and remain sane.

Sounds good...